Therefore, further validation at both the cellular and animal levels is needed to comprehensively elucidate the role of APRIL in IgG4-ROD and MALT lymphoma lacrimal gland lesions and to identify new therapeutic targets for them. Here, TNFSF13 is linked to MALT lymphoma.